Oric Pharmaceuticals filed an amendment to its 2022 equity incentive plan to further attract and retain key personnel, including grants that qualify as inducement grants under Nasdaq Listing Rule 5635. Analysts view this positively as an indication of continued leadership confidence and HR stability.